Kyongbo Pharmaceutical경보제약
214390 · KOSPI · ₩214390 · 경보제약
- Market cap
- ₩124B
- Enterprise value
- ₩266B
- P/E
- 25.3×
- P/B
- 0.8×
- Dividend yield
- 1.0%
- ROE
- 3.3%
- Net margin
- 1.7%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−44.4% from the high
₩4,700Today: ₩5,030 – ₩5,220₩9,300
Returns
- 1W−3.4%
- 1M−4.1%
- 3M+0.6%
- 6M−24.0%
- YTD−10.4%
- 1Y−9.8%
- Volume today
- 14,193
- 0.8× the 20-day average
- Traded today
- ₩73M
- Listed shares
- 23,906,860
- EPS (12 months)
- ₩205
- Earnings yield 4.0%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 39 of 100 (50 is a normal day for this stock).
- MomentumFlat-3.4% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Kyongbo Pharmaceutical stock overview
Kyongbo Pharmaceutical (경보제약, KRX: 214390) is listed on KOSPI, in the Biotech & Pharma sector. The company is a Korean pharmaceutical firm founded in 1987 that specializes in active pharmaceutical ingredients (APIs) and also sells finished drugs. Its shares closed at ₩5,170 on Oct 26, 2026, up 0.78% on the day, giving it a market value of ₩124B.
Key facts
- Market cap
- ₩124B
- Sector
- Biotech & Pharma
- Latest price change
- +0.78%
- As of
- Oct 26, 2026
- Main business
- The company is a Korean pharmaceutical firm founded in 1987 that specializes in active pharmaceutical ingredients (APIs) and also sells finished drugs.
Quick answers about Kyongbo Pharmaceutical
- What does Kyongbo Pharmaceutical do?
- The company is a Korean pharmaceutical firm founded in 1987 that specializes in active pharmaceutical ingredients (APIs) and also sells finished drugs. Its API business covers general APIs, cephalosporin APIs and anticancer APIs, and it exports to developed countries as well as supplying the domestic market. Its finished-drug business sells prescription products such as cardiovascular, anesthetic and antibiotic drugs, along with general medicines.
- What is the market cap of Kyongbo Pharmaceutical?
- The market capitalisation of Kyongbo Pharmaceutical was ₩124B at the close on Oct 26, 2026.
- Who are the largest shareholders of Kyongbo Pharmaceutical?
- According to the latest official filings, the largest reported holders are Chong Kun Dang Holdings (60.56%, as of Feb 11, 2026); National Pension Service (0.45%, as of Dec 31, 2025); Chae Hyeon-suk (0.05%, as of Jan 9, 2025).
- When is the next earnings report from Kyongbo Pharmaceutical?
- Korean companies rarely announce results dates in advance. Based on when Kyongbo Pharmaceutical filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Kyongbo Pharmaceutical?
- Yes. The National Pension Service held 0.45% of Kyongbo Pharmaceutical shares as of Dec 31, 2025.
Company profile
The company is a Korean pharmaceutical firm founded in 1987 that specializes in active pharmaceutical ingredients (APIs) and also sells finished drugs. Its API business covers general APIs, cephalosporin APIs and anticancer APIs, and it exports to developed countries as well as supplying the domestic market. Its finished-drug business sells prescription products such as cardiovascular, anesthetic and antibiotic drugs, along with general medicines. The company is also expanding into medical devices and animal health products, and is preparing to enter the global ADC anticancer CDMO market.
Written by AI from the company's latest annual report.
- Korean name
- 경보제약
- Sector
- Biotech & Pharma
- Themes
- Pharmaceuticals
- CEO
- 김태영
- Founded
- Mar 1987
- Listed
- Jun 2015
- Listed shares
- 23,906,860
- Fiscal year ends
- Month 12
- Website
- www.kbpharma.co.kr
Similar companies
- Samsung Biologics207940 · ₩67T₩1,452,000−0.95%
- Celltrion068270 · ₩44T₩190,000−2.26%
- Alteogen196170 · ₩15T₩218,500−2.67%
- Yuhan000100 · ₩6T₩81,700−3.54%
- SK biopharmaceuticals326030 · ₩5.9T₩75,800−1.43%
- HLB028300 · ₩5.2T₩39,250−5.65%
- Hanmi Pharm128940 · ₩4.5T₩352,500−2.49%
- SAM Chun Dang Pharm000250 · ₩4.4T₩188,900−5.17%
Recent filings
See all- [Amended Filing] Major Matters Report (Business Suspension)Sep 30, 2026
- [Amended Filing] Major Matters Report (Business Suspension)Aug 31, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Preliminary earningsJul 31, 2026
- Disclosure Related to Sustainability Management Report, etc. (Voluntary Disclosure)Jun 26, 2026
Titles in Korean until English translations are added.
Also known as: Kyongbo Pharmaceutical / 경보제약 / 214390 / KRX:214390
Source: KRX statistical information